| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Departments of Thoracic/Head and Neck Medical Oncology [S-Y. S., W. L., P. Y., W. K. H., R. L.] and Clinical Cancer Prevention [S. M. L.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
The induction of apoptosis by the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR) has been documented in vitro in various cancer types. A role for reactive oxygen species (ROS) in apoptosis induced by 4HPR in some cancer cells has been demonstrated recently. We studied five different human head and neck and five lung cancer cell lines to determine whether the ROS play a general role in 4HPR-induced apoptosis. We found that 4HPR induced apoptosis in all of the cell lines; however, this effect was blocked by antioxidants in only 2 of the 10 cell lines. 4HPR induced a greater than 4-fold increase in the generation of intracellular ROS in these two cell lines compared with a much lower effect in other cell lines. Furthermore, these two cell lines were most sensitive to the induction of apoptosis by 4HPR. The level of the cellular antioxidant thiol and superoxide dismutase activity were relatively lower in cells, which responded to 4HPR with a high level of ROS generation. These results indicate that although ROS can mediate 4HPR-induced apoptosis in some cells, which may have a low endogenous cellular antioxidant levels, other mechanisms exist for 4HPR-induced apoptosis. One such mechanism may involve retinoic acid receptors (RARs) because an RAR antagonist was able to block partially 4HPR-induced apoptosis. In conclusion, 4HPR-induced apoptosis involves at least three different mechanisms, which are complex and can overlap in the same cell line: (a) one mechanism involving 4HPR-induced ROS; (b) one involving RARs; and (c) at least one that does not involve ROS or RARs and remains unclear.
This article has been cited by other articles:
|
|
 |
|
  H. Kadara, E. Tahara, H.-J. Kim, D. Lotan, J. Myers, and R. Lotan Involvement of Rac in Fenretinide-Induced Apoptosis Cancer Res., June 1, 2008; 68(11): 4416 - 4423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Guilbault, J. B. De Sanctis, G. Wojewodka, Z. Saeed, C. Lachance, T. A. A. Skinner, R. M. Vilela, S. Kubow, L. C. Lands, M. Hajduch, et al. Fenretinide Corrects Newly Found Ceramide Deficiency in Cystic Fibrosis Am. J. Respir. Cell Mol. Biol., January 1, 2008; 38(1): 47 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Anding, J. S. Chapman, D. W. Barnett, R. W. Curley Jr., and M. Clagett-Dame The Unhydrolyzable Fenretinide Analogue 4-Hydroxybenzylretinone Induces the Proapoptotic Genes GADD153 (CHOP) and Bcl-2-Binding Component 3 (PUMA) and Apoptosis that Is Caspase- Dependent and Independent of the Retinoic Acid Receptor Cancer Res., July 1, 2007; 67(13): 6270 - 6277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Vene, G. Arena, A. Poggi, C. D'Arrigo, M. Mormino, D. M. Noonan, A. Albini, and F. Tosetti Novel cell death pathways induced by N-(4-hydroxyphenyl)retinamide: therapeutic implications Mol. Cancer Ther., January 1, 2007; 6(1): 286 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Zanardi, D Serrano, A Argusti, M Barile, M Puntoni, and A Decensi Clinical trials with retinoids for breast cancer chemoprevention. Endocr. Relat. Cancer, March 1, 2006; 13(1): 51 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zou, P. Yue, N. Lin, M. He, Z. Zhou, S. Lonial, F. R. Khuri, B. Wang, and S.-Y. Sun Vitamin C Inactivates the Proteasome Inhibitor PS-341 in Human Cancer Cells Clin. Cancer Res., January 1, 2006; 12(1): 273 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shishodia, A. M. Gutierrez, R. Lotan, and B. B. Aggarwal N-(4-Hydroxyphenyl)Retinamide Inhibits Invasion, Suppresses Osteoclastogenesis, and Potentiates Apoptosis through Down-regulation of I{kappa}B{alpha} Kinase and Nuclear Factor-{kappa}B-Regulated Gene Products Cancer Res., October 15, 2005; 65(20): 9555 - 9565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Park, L. Liu, I.-H. Kim, J.-H. Kim, K.-R. You, and D.-G. Kim Identification of the Genes Involved in Enhanced Fenretinide-Induced Apoptosis by Parthenolide in Human Hepatoma Cells Cancer Res., April 1, 2005; 65(7): 2804 - 2814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Moreb, A. Gabr, G. R. Vartikar, S. Gowda, J. R. Zucali, and D. Mohuczy Retinoic Acid Down-Regulates Aldehyde Dehydrogenase and Increases Cytotoxicity of 4-Hydroperoxycyclophosphamide and Acetaldehyde J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 339 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Bayon, M. A. Ortiz, F. J. Lopez-Hernandez, P. H. Howe, and F. J. Piedrafita The Retinoid Antagonist MX781 Induces Clusterin Expression in Prostate Cancer Cells via Heat Shock Factor-1 and Activator Protein-1 Transcription Factors Cancer Res., August 15, 2004; 64(16): 5905 - 5912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-Y. Sun, N. Hail Jr, and R. Lotan Apoptosis as a Novel Target for Cancer Chemoprevention J Natl Cancer Inst, May 5, 2004; 96(9): 662 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Gopal, J. M. Pagel, N. Hedin, and O. W. Press Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism Blood, May 1, 2004; 103(9): 3516 - 3520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lango, A. L. Wentzel, J. I. Song, S. Xi, D. E. Johnson, W. W. Lamph, L. Miller, and J. R. Grandis Responsiveness to the Retinoic Acid Receptor-selective Retinoid LGD1550 Correlates with Abrogation of Transforming Growth Factor {alpha}/Epidermal Growth Factor Receptor Autocrine Signaling in Head and Neck Squamous Carcinoma Cells Clin. Cancer Res., September 15, 2003; 9(11): 4205 - 4213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-H. Chun, D. M. Benbrook, K. D. Berlin, W. K. Hong, and R. Lotan The Synthetic Heteroarotinoid SHetA2 Induces Apoptosis in Squamous Carcinoma Cells through a Receptor-independent and Mitochondria-dependent Pathway Cancer Res., July 1, 2003; 63(13): 3826 - 3832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Sabichi, M. R. Modiano, J. J. Lee, Y.-M. Peng, M.-J. Xu, H. Villar, W. S. Dalton, and S. M. Lippman Breast Tissue Accumulation of Retinamides in a Randomized Short-term Study of Fenretinide Clin. Cancer Res., July 1, 2003; 9(7): 2400 - 2405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Tosetti, R. Vene, G. Arena, M. Morini, S. Minghelli, D. M. Noonan, and A. Albini N-(4-Hydroxyphenyl)retinamide Inhibits Retinoblastoma Growth through Reactive Oxygen Species-Mediated Cell Death Mol. Pharmacol., March 1, 2003; 63(3): 565 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zou, A.-T. Vlastos, L. Yang, J. Wang, M. Brewer, and M. Follen Effect of 4-Hydroxyphenylretinamide on Human Cervical Epithelial and Cancer Cell Lines Reproductive Sciences, January 1, 2003; 10(1): 41 - 48. [Abstract] [PDF]
|
|
|
|
 |
|
 W. F. Holmes, D. R. Soprano, and K. J. Soprano Elucidation of Molecular Events Mediating Induction of Apoptosis by Synthetic Retinoids Using a CD437-resistant Ovarian Carcinoma Cell Line J. Biol. Chem., November 15, 2002; 277(47): 45408 - 45419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-G. Kim, K.-R. You, M.-J. Liu, Y.-K. Choi, and Y.-S. Won GADD153-mediated Anticancer Effects of N-(4-Hydroxyphenyl)retinamide on Human Hepatoma Cells J. Biol. Chem., October 4, 2002; 277(41): 38930 - 38938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. Simeone, S. Ekmekcioglu, L. D. Broemeling, E. A. Grimm, and A. M. Tari A Novel Mechanism by Which N-(4-hydroxyphenyl)retinamide Inhibits Breast Cancer Cell Growth: The Production of Nitric Oxide Mol. Cancer Ther., October 1, 2002; 1(12): 1009 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Lovat, S. Oliverio, M. Ranalli, M. Corazzari, C. Rodolfo, F. Bernassola, K. Aughton, M. Maccarrone, Q. D. C. Hewson, A. D. J. Pearson, et al. GADD153 and 12-Lipoxygenase Mediate Fenretinide-induced Apoptosis of Neuroblastoma Cancer Res., September 15, 2002; 62(18): 5158 - 5167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-R. You, J. Wen, S.-T. Lee, and D.-G. Kim Cytochrome c Oxidase Subunit III. A MOLECULAR MARKER FOR N-(4-HYDROXYPHENYL)RETINAMIDE-INDUCED OXIDATIVE STRESS IN HEPATOMA CELLS J. Biol. Chem., February 1, 2002; 277(6): 3870 - 3877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Follen, E. N. Atkinson, D. Schottenfeld, A. Malpica, L. West, S. Lippman, C. Zou, W. N. Hittelman, R. Lotan, and W. K. Hong A Randomized Clinical Trial of 4-Hydroxyphenylretinamide for High-Grade Squamous Intraepithelial Lesions of the Cervix Clin. Cancer Res., November 1, 2001; 7(11): 3356 - 3365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Smith and B. Anderson Where to Next with Retinoids for Cancer Therapy? Clin. Cancer Res., October 1, 2001; 7(10): 2955 - 2957. [Full Text] [PDF]
|
|
|
|
|
|
D. Shan, A. K. Gopal, and O. W. Press Synergistic Effects of the Fenretinide (4-HPR) and Anti-CD20 Monoclonal Antibodies on Apoptosis Induction of Malignant Human B Cells Clin. Cancer Res., August 1, 2001; 7(8): 2490 - 2495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gupta, R. Nines, K. A. Rodrigo, R. A. Aziz, P. S. Carlton, D. L. Gray, V. E. Steele, M. A. Morse, and G. D. Stoner Effects of Dietary N-(4-Hydroxyphenyl)retinamide on N-Nitrosomethylbenzylamine Metabolism and Esophageal Tumorigenesis in the Fischer 344 Rat J Natl Cancer Inst, July 4, 2001; 93(13): 990 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-Y. Sun, P. Yue, G. J. Kelloff, V. E. Steele, S. M. Lippman, W. K. Hong, and R. Lotan Identification of Retinamides That Are More Potent than N-(4-Hydroxyphenyl)retinamide in Inhibiting Growth and Inducing Apoptosis of Human Head and Neck and Lung Cancer Cells Cancer Epidemiol. Biomarkers Prev., June 1, 2001; 10(6): 595 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-J. Don, Y.-H. Chang, K.-K. Chen, L.-K. Ho, and Y.-P. Chau Induction of CDK Inhibitors (p21WAF1 and p27Kip1) and Bak in the {beta}-Lapachone-Induced Apoptosis of Human Prostate Cancer Cells Mol. Pharmacol., April 1, 2001; 59(4): 784 - 794. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. K. Hong, M. R. Spitz, and S. M. Lippman Cancer Chemoprevention in the 21st Century: Genetics, Risk Modeling, and Molecular Targets J. Clin. Oncol., November 1, 2000; 18(90001): 9s - 18. [Full Text] [PDF]
|
|
|
|
|
|
A. Decensi, R. Torrisi, S. Bruno, M. Costantini, A. Curotto, G. Nicolò, B. Malcangi, L. Baglietto, G. P. Bruttini, B. Gatteschi, et al. Randomized Trial of Fenretinide in Superficial Bladder Cancer Using DNA Flow Cytometry as an Intermediate End Point Cancer Epidemiol. Biomarkers Prev., October 1, 2000; 9(10): 1071 - 1078. [Abstract] [Full Text]
|
|
|
|
|
|
S. M. Lippman and P. H. Brown Tamoxifen Prevention of Breast Cancer: an Instance of the Fingerpost J Natl Cancer Inst, November 3, 1999; 91(21): 1809 - 1819. [Full Text] [PDF]
|
|
|
|
|
|
W. McCaskill-Stevens, E. T. Hawk, P. J. Flynn, and S. M. Lippman National Cancer Institute-Supported Cancer Chemoprevention Research: Coming of Age J. Clin. Oncol., November 1, 1999; 17(90001): 53 - 62. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
